El­e­vate­Bio and Affi­ni-T part­ner on KRAS ther­a­pies; Cas­ma rais­es $46M to drug the cell’s garbage dis­pos­al sys­tem

Affi­ni-T is the lat­est to sign on with El­e­vate­Bio, for­mer Alex­ion head David Hal­lal’s one-stop-shop for cell and gene ther­a­py man­u­fac­tur­ing. Affi­ni-T will use El­e­vate­Bio …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER